A Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab in Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Rilotumumab (Primary) ; Capecitabine; Cisplatin
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
- 24 Nov 2014 Status changed from active, no longer recruiting to discontinued, according to an Amgen media release.
- 27 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Feb 2013 New trial record